Imdevimab

• Description :

  Imdevimab (REGN10987) is a human monoclonal antibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins[1][2].

• Product Name Alternative :

  REGN10987

• UNSPSC :

  12352203

• Target :

  SARS-CoV

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/imdevimab.html

• Purity :

  95.00

• Solubility :

  10 mM in DMSO

• Smiles :

  [Imdevimab]

• Molecular Weight :

  (144.14 kDa)

• References & Citations :

  [1]Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD) : National Institute of Child Health and Human Development; 2006–. Casirivimab. 2022 May 15. |[2]Tada, T., et al., (2021) . Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies. bioRxiv : the preprint server for biology, 2021.02.18.431897.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 4

• CAS Number :

  [2415933-40-1]